Cost of vision loss estimated at nearly $3 trillion globally, says AMD Alliance

19 April 2010

The AMD Alliance International (AMDAI) released the first-ever estimates of global cost of vision loss ' put at $2,954 billion for the 733 million people living with low vision and blindness worldwide in 2010 ' at its Global Congress held in Vienna, Austria, last week.

Even more importantly, these costs are set to rise dramatically through to 2020 unless effective prevention and treatment strategies are adopted worldwide. Current costs include direct health care expenditure, informal caregiver time, lost productivity and inefficiencies in raising tax revenue to fund health care.

'The findings from this study represent the most definitive data available about the worldwide cost of vision loss,' said Alan Cruess, professor and Head District Chief Department of Ophthalmology, Dalhousie University (Canada), and chairman of the AMDAI's Scientific Advisory Panel. Penny Hartin, chief executive of the World Blind Union, added: 'With continued population growth, we know these costs will spiral upwards, and overburden global health care systems unless we take preventative action now. This ground-breaking research gives us the tools we need for continued advocacy with the United Nations and governments.'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Pharmaceutical